Developing Nepal’s medicines pricing policy: evidence synthesis and stakeholders’ consultation-Reference-Cited by-同舟云学术

Developing Nepal’s medicines pricing policy: evidence synthesis and stakeholders’ consultation

Published:2024-04-29 Issue:1 Volume:17 Page:
ISSN:2052-3211
Container-title:Journal of Pharmaceutical Policy and Practice
language:en
Short-container-title:Journal of Pharmaceutical Policy and Practice

Author:

Babar Zaheer-Ud-Din¹^ORCID,Dulal Santosh²,Dhakal Narayan Prasad³,Upadhyaya Madan Kumar⁴,Trap Birna²

Affiliation:

1. Department of Pharmacy, University of Huddersfield, Huddersfield, UK

2. USAID Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program, Management Sciences for Health, Kathmandu, Nepal

3. Department of Drug Administration, Ministry of Health and Population, Kathmandu, Nepal

4. Quality Standard and Regulation Division, Ministry of Health and Population, Kathmandu, Nepal

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/20523211.2024.2346222

Reference55 articles.

1. Pharmaceutical pricing policies in Qatar and Lebanon: narrative review and document analysis

2. Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon

3. Babar Z. U. Pharmaceutical Prices in the 21st Century 2015 X 411 p. http://www.springer.com/adis/book/978-3-319-12168-0.

4. Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan

5. Cost–plus pricing for setting the price of pharmaceutical products. WHO guideline on country pharmaceutical pricing policies. A plain language summary ISBN 978-92-4-002469-4 (electronic version) ISBN 978-92-4-002470-0 (print version) © World Health Organization 2021. https://apps.who.int/iris/bitstream/handle/10665/341902/9789240024694-eng.pdf.